SEC 13F Intelligence

Managers / Q3 2021

Healthcare Value Capital, LLC

CIK 0001458461 · 50 TICE BLVD, SUITE 140, WOODCLIFF LAKE, NJ, 07677 · 212-488-5411

Reported Value
$51M
Q3 2021
Positions
25
Filings on Record
12
2019–present window
Filed
Nov 15, 2021
original filing

Summary

Healthcare Value Capital, LLC reported $51M in U.S.-listed holdings across 25 positions for Q3 2021.

Its largest position, GILD, represents 8.3% of the portfolio.

Compared with Q2 2021, the fund opened 3 new positions and exited 2.

Portfolio Metrics

Turnover
+18.6%
vs prior filed quarter
Top-10 Concentration
+61.5%
share of reported value
Largest Position
+8.3%
Gilead Sciences
New / Exited
3 / 2
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $26MQ1 ’19Q2 ’19: $53MQ3 ’19: $55MQ3 ’19Q4 ’19: $34MQ1 ’20: $59MQ1 ’20Q2 ’20: $39MQ3 ’20: $30MQ3 ’20Q4 ’20: $30MQ1 ’21: $45MQ1 ’21Q2 ’21: $50MQ3 ’21: $51MQ3 ’21filingsflow.com

Portfolio Composition

By security type
Common Stock: 64.5%Other: 27.1%ADR: 5.9%ETP: 2.4%
  • Common Stock · 64.5% · $33M
  • Other · 27.1% · $14M
  • ADR · 5.9% · $3M
  • ETP · 2.4% · $1M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
PROSHARES TR IINEW+50.0K50.0K+$1M$1M
VRTXVERTEX PHARMACEUTICALS INCNEW+5.0K5.0K+$907,000$907,000
DURECT CORPNEW+250.0K250.0K+$320,000$320,000
PROSHARES TRADDED+100.0K150.0K+$2M$3M
COLLCOLLEGIUM PHARMACEUTICAL INCSOLD OUT−100.0K0−$2M$0
MDXGMIMEDX GROUP INCSOLD OUT−125.0K0−$2M$0
PROSHARES TRADDED+100.0K200.0K+$812,000$2M
PROSHARES TR IITRIMMED−12.5K12.5K−$317,000$285,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2021

18 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1GILDGILEAD SCIENCES INChistory →COM8.27%$4M60.0K
2GLAXOSMITHKLINE PLCSPONSORED ADR7.54%$4M100.0K
3PFEPFIZER INChistory →COM6.37%$3M75.0K
4ALKSALKERMES PLChistory →SHS6.09%$3M100.0K
5AMRYT PHARMA PLCSPONSORED ADS5.97%$3M250.0K
6MRKMERCK & CO INChistory →COM5.93%$3M40.0K
7AZNNASTRAZENECA PLChistory →SPONSORED ADR5.93%$3M50.0K
8BMYBRISTOL-MYERS SQUIBB COhistory →COM5.84%$3M50.0K
9IRWDIRONWOOD PHARMACEUTICALS INChistory →COM CL A5.16%$3M200.0K
10CLOVIS ONCOLOGY INCCOM4.40%$2M500.0K
11TYME TECHNOLOGIES INCCOM4.07%$2M2.00M
12ANTARES PHARMA INCCOM3.59%$2M500.0K
13VRTXVERTEX PHARMACEUTICALS INChistory →COM1.79%$907,0005.0K
14GREENLANE HLDGS INCCL A1.64%$830,000350.0K
15VYNE THERAPEUTICS INCCOM1.10%$556,000400.0K
16ADAMAS PHARMACEUTICALS INCCOM0.97%$491,000100.0K
17GAMIDA CELL LTDSHS0.77%$392,000100.0K
18DURECT CORPCOM0.63%$320,000250.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2021$51M25Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$50M23Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$45M22May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$30M17Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$30M18Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$39M19Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$59M26May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$34M16Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$55M22Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$53M19Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$26M10May 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.